HYDROCHLOROTHIAZIDE; LISINOPRIL | N019888 | ALMATICA PHARMA LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Premier Research International, LLC FDA-2025-P-7282 Premier Research International, LLC filed this ANDA Suitability Petition pursuant to section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA confirm that Lisinopril and Hydrochlorothiazide Powder for Oral Suspension is suitable for submission as an Abbreviated New Dr | Suitability | 2025-12-22 | Open | Premier Research International |
Suitability Petition from Premier Consulting FDA-2024-P-3573 Premier Consulting filed this suitability petition on July 29, 2024, pursuant to section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act, requesting FDA confirmation that Lisinopril and Hydrochlorothiazide Oral Liquid is suitable for submission as an Abbreviated New Drug Application (ANDA), | Suitability | 2024-07-30 | Open | Premier Consulting |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.